The Role of Substance P in Neurodegenerative Diseases

Atefeh Ghahremanlou¹,², Fariba Mohammadi¹, Seyed Isaac Hashemy¹,³

¹ Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
² Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
³ Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Received: 08 Feb. 2020; Accepted: 28 Jun. 2020

Abstract: Tachykinins (TKs) are a family of neuropeptides widely distributed in the human body, especially in the nervous system. TKs have exhibited both neuroprotective and neurodegenerative properties in the central nervous system (CNS) and spinal cord. Also, several studies have shown that substance P (SP), as a pioneering neuropeptide of the TK family, is engaged in the pathogenesis of neurodegenerative disorders (NDs), such as Alzheimer disease, Multiple Sclerosis, Parkinson’s disease, Huntington’s disease, and Amyotrophic lateral sclerosis. However, a huge body of information available about the level of SP in NDs demonstrates that SP and its receptors might be prognostic or diagnostic factors for NDs. The present review article summarizes the roles of TKs in common neurodegenerative disorders.

Keywords: Tachykinins; Tachykinin receptors; Substance P; Neurodegenerative disorders

Introduction

Some neurological disorders with an unknown etiology are unique to the human nervous system. Neurodegenerative disorders (NDs) such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Multiple Sclerosis (MS), Huntington’s disease (HD), and Amyotrophic lateral sclerosis (ALS) are assessed by clinical criteria, laboratory investigations, and functional neuroimaging (1-3). The diagnostic accuracy of these diseases varies depending on the type of neurodegenerative disease. In many cases, the diagnosis remains unknown until death; and during the course of the disease, NDs can be improved by medications but never cured (4). Therefore, the expansion of biomarkers that may evaluate the risk of disease, presence, and progression is one of the major aims and challenges in research on NDs. In this regard, there are no confirmed biomarkers that can be used to reliably diagnose NDs or prevent their progression with high sensitivity and specificity. Thus, a large number of biomarkers may be required to detect these patients. Recently, several studies on NDs have suggested that TKs, as a diagnostic biomarker for NDs, might play important roles in CNS since they have both neuroprotective and neurodegenerative properties (5,6). Therefore, the purpose of this review article is to summarize the roles of TKs in common NDs such as AD, MS, PD, HD, and ALS.

Mammalian tachykinins

Tachykinins are a family of neuropeptides (10-11 amino acids) characterized by a conserved motif (Phe-X-Gly-Leu-Met-NH2) in their C-terminal (7,8). Several TK peptides have been identified in mammalian cells including substance P (SP), hemokinin-1 (HK-1), neurokinin B (NKB), neurokinin A (NKA), and N-terminally extended forms of NKA such as neuropeptide K (NPK) and neuropeptide γ (NPγ) (9). Generally, three genes are responsible for coding these neuropeptides, including Tac1 (pre-pro-tachykinin-A, Ppt-a), Tac3 (Ppt-b), and Tac4 (Ppt-c). SP, NKA, NPK, and NPγ are encoded by Tac1 while NKB and HK-1 are encoded by Tac3 and Tac4, respectively (10). These neuropeptides are mainly expressed in the nervous and immune systems (9,11,12). SP and NKA are released from the nerve endings in the spinal cord and peripheral nerves, acting as excitatory neurotransmitters. Although SP is often expressed in enteric neurons, it can be produced in immune cells during inflammatory processes, as well. NKB is present in the central nervous system (CNS) and spinal cord. In addition, HK-1 is a novel SP-like peptide that exists in non-neuronal cells and tissues (8,9,11,13).

The effects of TKs by interacting with specific
receptors, named neurokinin 1 receptor (NK1R), NK2R, and NK3R (8,14). These receptors, as small proteins belonging to the family of G protein-coupled membrane receptors (GPCRs), contain 350 to 500 amino acids. Each TK peptide prefers binding to a specific receptor with a higher affinity than any other TKs (15,16). For instance, SP and HK-1 prefer to interact with the NK1 receptor, while NKA and NKB have a higher affinity for the NK2R and NK3R, respectively (9,10,16). After binding of TKs to their receptors, it has been shown that they utilize the phospholipase C system as a second messenger. The activated phospholipase C leads to the hydrolysis of phosphoinositol and increased intracellular calcium levels (17). Subsequently, the activation of TK receptors causes various biological activities, including neurogenic inflammation, hematoipoiesis, smooth muscle contraction, emotional behavior, vasodilation, immune system activation, pain transmission, and stimulation of endocrine gland secretion (14,18,19). Besides, they are involved in the pathophysiology of several diseases, such as breast and endometrial cancer (20,21).

The effect of tachykinins in neurodegenerative diseases NDs are chronic and progressive diseases associated with selective and symmetric loss of neurons in motor, sensory, or cognitive systems (22). Although there is still no evidence of the neuropathic role of a specific neuropeptide in a particular ND, some neuropeptide levels might change in some of these disorders (23-26). Moreover, it has been shown that TKs can have neurotrophic effects on central neurons and NDs, probably due to the absence or loss of TKs in selected regions of the brain and spinal cord (19). SP was recognized as the first neuroactive TK and was the first one suggested to be a neurotransmitter (27). In addition, it has frequently shown a widespread distribution in the CNS of mammals, including humans, and has been detected with different effects in normal and pathological conditions (28,29). In this paper, it is hypothesized that SP as an important member of the TKs family, shows a neurotrophic activity on central neurons, and the defects involving SP in the selected regions may lead to various NDs (as shown in Figure 1).

Alzheimer disease (AD) AD is one of the irreversible neurodegenerative disease, which is clinically characterized by progressive impairments of memory and cognition and the neuronal loss in the various regions of the brain (30). Histopathologically, several studies have suggested that the hallmarks of AD are the accumulation of insoluble beta-amyloid (Aβ) fibrils in senile plaques that play an important role in the onset and development of the disease (31-33). Aβ is one of the main components of senile plaques in AD (34) that a special segment of it (amino acids 1 to 40) has been shown to mediate both neurotrophic and neurotoxic properties. In this line, Yankner et al., showed that Aβ (amino acids 1 to 40) exhibits neurotrophic effects in undifferentiated rat embryonic hippocampal neurons in low concentrations, while it has neurotoxic effects at high concentrations. Neuronal degeneration may occur in mature neurons as a result of the accumulation of high Aβ concentrations, as occurs in AD (35). Moreover, the association of TKs with AD was first proposed by Yankner et al., who determined that some sequences of Aβ (amino acids 25 to 35) have homology to SP, and this sequence could function as SP antagonists. In addition, according to Kowall et al., the partial sequence of Aβ (25-35) might have the ability to act as an SP antagonist by interacting with its SP receptors (36).

In contrast to these studies, several studies have demonstrated the lack of any interaction between Aβ and SP receptors (37,38). This view is supported by Kimura et al., who observed that Aβ (1-40) could only weakly activate the SP receptors, whereas, in the presence of glutamate as a synergist, it enhances SP receptors activation in vitro (39). Aβ, along with glutamate, stimulates phosphatidylinositol production and subsequently increases intracellular calcium, which ultimately leads to neuronal cell death (40,41). In this context, El-Agnaf et al., also reported that Aβ (25 to 35) has the same properties as SP in the presence of phenylalanine at position 31, whereas it reverses these properties after replacement of phenylalanine with an isoleucine residue at this position (34).

It is also well established from a variety of studies that SP in the brain plays a positive role in memory and learning processes, which is probably because of an increase in the effect of dopamine neurotransmitters in synaptic spaces. According to this study, the reduction or lack of SP expression possibly involves in the pathogenesis of AD (42). In most studies of AD patients, decreased the level of SP immunoreactivity is reported in different parts of the brain cortex in patients group compared to the control group (43,44). In addition, both depletion and increased SP in CSF have been observed in manifest AD (45-48). Moreover, several lines of evidence suggest that the reduction in SP level may occur in the neurons that are subject to choline acetyltransferase activity reduction as a specific biochemical feature in the
AD, or maybe due to several simultaneous changes in the neurochemical systems in this disease (49,50). Moreover, the hydrolysis of SP is also reported in AD as a reason for the reduction of SP level. The degradation of SP is catalyzed by the enzyme prolyl endopeptidase (PEP), which cleaves the SP’s proline residue from the C-terminal (51). The literature on PEP has highlighted that the enzyme is involved in the formation of Aβ, and its activity is higher in AD patients (52,53). In contrast with these findings, some studies have reported the lack of any significant difference in the level of SP in the AD patients compared to the control group. These different results seem to depend on the type of population despite the many studies conducted to confirm the decreased level of SP in AD (54,55).

Multiple sclerosis (MS)

Multiple sclerosis (MS) is a common neurological and autoimmune disorder typically characterized by focal regions of inflammation, demyelination, and gliosis in the grey matter of the CNS (56,57). Both innate and adaptive immune responses play a key role in the development of MS, but it is mainly affected by T cells (of Th1, Th17) (58,59). Previous studies have reported that SP can play an essential role in activating autoimmune T cells by increasing pro-inflammatory cytokine production, which can up-regulate SP and NK1R expression, and incite antigen-presenting cells to produce more T cell stimulatory cytokines (60-62). For instance, Vilissaar et al., proposed a model whereby immunocyte derived SP stimulates migration of Th1 and Th17 autoreactive cells to the CNS through the blood-brain barrier (BBB) by increasing pro-inflammatory cytokines including IL-12 and IL-23 (63). In addition, SP may enhance the permeability of BBB by interacting with NK1R on endothelial cells that allow an influx of immune mediators and activated T cells to the CNS, which can interact with astrocytes and oligodendroglia, leading to further release of cytokines and SP (64,65). Thereafter, SP can act via NK1R on the various cellular components of the MS plaque, such as lymphocytes, macrophages, and glia, to increase proliferative and pro-inflammatory responses. An increase in the level of SP can lead to the progression of inflammation to demyelination and gliosis (56). Further study was accomplished in order to clarify the role of the SP/NK1R system in the MS and interpretation of results showed that this system could contribute to the augmentation of CNS inflammation in MS (66). Also, they concluded that treatment with NK1R antagonists might improve the success of the treatment of MS. Furthermore, Kostyk et al., examined alterations in the expression of SP in patients with MS and showed that the expression of SP in astrocytes at the plaque site significantly increased compared to the control group (67). In contrast, Rösler et al., reported that the level of SP in the CSF tended to increase in all subgroups of MS patients, but showed no significant differences with the control group (68).

Parkinson’s disease (PD)

PD is a progressive ND that is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) (69). Various secondary disorders occur due to the degeneration of dopaminergic neurons, e.g., inflammation, BBB dysfunction, oxidative stress, glutamate excitotoxicity, and mitochondrial dysfunction (70). The current treatment for PD is L-3,4-dihydroxyphenylalanine (L-DOPA). This product does not prevent the degeneration of neurons and, at the same time, replaces the lost dopamine and prevents its breakdown (71). It has been determined that L-DOPA causes a change in the signaling pathways of the brain and may also lead to abnormal involuntary movements in the patients (72). In recent years, several efforts have been focused on extending new neuroprotective therapies in order to treat the main cause of PD. Previous studies have recognized the SP and its receptor (NK1R) as new neuroprotective targets (71,73). In this context, several investigations have provided multiple conclusions from measurements of SP level in the CSF of PD patients. Nutt et al., reported that the level of SP is decreased slightly in their CSF samples (74). On the other hand, Pezzoli et al., found that the level of SP is increased in Parkinson patients with severe disability compared to non-symptomatic neurological controls (75). However, a study by Cramer et al., showed a lack of any significant difference between patients with PD and the control group in the CSF level of SP (76). The reason for such different results might be due to the type of patients studied or the cross-reactivity of the radioimmunoassay technique used for the determination of SP (77).

In brain regions, the detection was almost consistent. The findings showed that the SP level is significantly decreased in substantia nigra pars compacta and pars reticulata (78-80). Nevertheless, the researchers have recognized the lack of any relation between the reduction of SP level and intensity of the disease (80). A considerable amount of studies has been conducted to determine the pathology of PD and found that the primary event of PD is the loss of SP activity in the substantia nigra (SN). These studies introduce a lack of dopamine as a secondary response (81). In contrast, another research
reported that the lack of dopaminergic drive leads to the reduction of SP expression in the SN. Also, they found that in the early stage of PD, in which dopamine neurons remain, the SP expression in the SN is normal or even elevated (82). To determine the effects of SP, Thornton et al., (2012) demonstrated that the enhancement of SP level accelerates disease progression, whereas treatment with NK1R antagonists preserves dopaminergic neurons and maintains BBB integrity in vitro. In addition to the mentioned results, they also found that the SP receptor antagonist alleviates neuroinflammation and induces the progression of motor function (73).

**Other neurodegenerative diseases**

A number of other NDs, such as Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), have been studied for alterations in TKs levels. HD is an autosomal dominant neurological disorder related to the dysfunction and degeneration of some parts of the brain, especially in the ganglia basal region (83). In the clinical course, the disease is accompanied by brain weight loss, a substantial reduction in basal ganglia size, and atrophy of brainstem regions (84). Moreover, in this disease, there is a decrease in the number of neurotransmitters, like SP, especially in the SN and basal ganglia. In other parts of the brain, such as thalamus and hypothalamus, there is no significant difference in the concentration of SP between patients and healthy groups (83). Several investigations have shown that SP could increase the release of striatal dopamine by sending a projection to the SN, and SP-containing striatal neurons can have a feedback loop with dopaminergic input (85,86). Accumulating evidence revealed that the SP might directly or indirectly affect the modulation of the sterility neurons function (87). In fact, the reduction of SP level is the first change in the level of neuropeptides in HD (88). Beal et al., were the first who studied the SP level at the core of the striatal terminals and the subthalamic nucleus. They found that there is a considerable reduction in SP-like immunoreactivity (SPLI) in both regions; indeed, SP-depletion is the first case of neurochemical deficiency found in subthalamic cores in HD (87). In a study, immunohistochemistry was tested on patients with HD and found that the level of SP is decreased significantly in the SN and globus pallidus (89). Similarly, Gale et al., showed that the concentration of SP in the SN and globus pallidus is significantly reduced in Huntington patients compared to controls (90).

Amyotrophic lateral sclerosis (ALS) is another ND, which is associated with changes in the SP level in the CNS. However, studies on this disease are limited and, therefore, difficult to conclude. ALS is an ND that primarily targets the motor neurons of the CNS (91). Its symptoms are the combination of the lower motor neuron (i.e., wasting, fasciculation, and hypotonia) and upper motor neuron signs (i.e., hypertonia, spasticity, and weakness) (92). Several lines of evidence suggest that the main cause of the onset and progression of ALS is still unknown (93), but there is growing evidence that the level of SP as a biomarker may be affected in this disease. CSF biomarkers such as SP could represent neuronal cell loss at an early stage of the disease. For example, Matsuishi et al., reported that the concentration of SP in the CSF of ALS patients was higher than in control groups (94). Furthermore, in another study, the distribution of NK1R was detected at the spinal cord of ALS patients. Also, they showed a significant reduction in SP binding, especially in the ventral horn that is associated with the loss of motor neurons. The results of this study suggested that the localization of receptors of SP to the ventral horn motor neurons in the human spinal cord that can justify the role of SP in the function of motor neurons in the disease (95). In addition, Gilberg et al., demonstrated that there is no significant decrease in the level of SPLI in patients with ALS, but the level of SPLI tends to decrease compared with a control group (96). In summary, there is slight evidence to show the changes in the SP level and its receptors in the ALS disease or to consider its changes as a secondary conclusion of the loss of motor neurons.

Regarding the vast distribution of TKs and TK receptors in the specific regions of the brain and spinal cord in addition to their participation in various types of inflammatory and immune diseases, the present study was conducted to summarize the effects of TKs on NDs. There are many investigations that show the roles of TKs in NDs. From the studies conducted in this regard, some conflicting results have been reported. However, these studies have majorly shown that SP is the most important factor in neurological diseases among the TK family. In the investigations discussed above (as summarized in Table 1), the reduction of SP level has been identified as a primary event in NDs, even though there is not enough information to support the view that the loss of SP is the main event in any of these disorders. In contrast, the existing literature on the change of SP level has also highlighted that the alteration of SP concentration is a secondary change in NDs, but there is not enough data to guarantee this view. Based on the findings reported in this manuscript, SP level, and its receptor (NK1R) are known as the most important prognostic and diagnostic factors in NDs. Nevertheless, the investigations listed above did not provide information about the exact roles of SP in NDs.
and are full of conflicts. The question raised by the present study is, “what is the most important reason for getting different results from those observed in this article?” Hence, it is required to conduct a larger number of and more extensive studies to determine the roles of SP and other TKs in NDs.

Figure 1. Alteration of SP level in various regions of the nervous system can relate to neurodegenerative disorders

Table 1. Changes in the level of SP in various Neurodegenerative disorders

| Neurodegenerative disorders   | Representative studies                                                                                                                                 |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Alzheimer disease            | The level of CSF SP in AD patients is higher than patients with other dementias and healthy controls. (46) SP is significantly lower in CSF of AD patients compared to controls (45). The quantitative level of SP had a relative reduction in the cerebral cortex (43). Considerable reductions in SP in various cortical areas and hippocampus in the brain of patients (44). SP significantly is lower in cerebral cortical regions of patients with clinical and pathological evidence of AD (49). No significant difference is seen in SP in the brain and spinal cord areas of AD patients compared to controls (54, 55). The expression of SP in astrocytes at the plaque site in patients with MS increased compared to the control group (67). No significant difference was observed between the subgroups of MS patients and the control group in the CSF level of SP (68). A slight, but not significantly different, reduction in CSF levels of SP (74) No significant difference between late-onset patients with PD and the control group in the CSF level of SP (76) Significant elevation in CSF levels of SP in Parkinson patients with severe disability compared to non-symptomatic neurological controls (75) The significant decrease in SP in the substantia nigra in postmortem brains from Parkinson patients compared to controls (78-80) The primary pathology of PD is a loss of action of SP in the substantia nigra, and the degeneration of the dopaminergic neurons is a secondary response (83). The dopaminergic neurons lead to a decrease in the nigral SP expression. But, in the early stage of PD, in which dopamine neurons remained, the nigral SP expression showed no change or even increased (73). SP level in the CSF of ALS patients was higher than that in the control groups (94). A marked reduction in SP binding with its receptors in the ventral horn (95) No significant decrease was observed in the level of SPLI in patients with ALS, but the level of SPLI tended to decrease compared with control (96). SP levels markedly declined in the core of the stria terminals and the subthalamic nucleus (87). The level of SP decreases considerably in the substantia nigra and globus pallidus (89). SP levels declined in the substantia nigra and globus pallidus (90). The amount of SP in the spinal cord is not markedly reduced (74). |
| Multiple Sclerosis          | No significant difference was observed between the subgroups of MS patients and the control group in the CSF level of SP (68). A slight, but not significantly different, reduction in CSF levels of SP (74) No significant difference between late-onset patients with PD and the control group in the CSF level of SP (76) Significant elevation in CSF levels of SP in Parkinson patients with severe disability compared to non-symptomatic neurological controls (75) The significant decrease in SP in the substantia nigra in postmortem brains from Parkinson patients compared to controls (78-80) The primary pathology of PD is a loss of action of SP in the substantia nigra, and the degeneration of the dopaminergic neurons is a secondary response (83). The dopaminergic neurons lead to a decrease in the nigral SP expression. But, in the early stage of PD, in which dopamine neurons remained, the nigral SP expression showed no change or even increased (73). SP level in the CSF of ALS patients was higher than that in the control groups (94). A marked reduction in SP binding with its receptors in the ventral horn (95) No significant decrease was observed in the level of SPLI in patients with ALS, but the level of SPLI tended to decrease compared with control (96). SP levels markedly declined in the core of the stria terminals and the subthalamic nucleus (87). The level of SP decreases considerably in the substantia nigra and globus pallidus (89). SP levels declined in the substantia nigra and globus pallidus (90). The amount of SP in the spinal cord is not markedly reduced (74). |

References

1. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-β deposits in vivo. J Cereb Blood Flow Metab 2002;22:1035-41.

2. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan
The role of substance P

ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002;61:797-805.

3. Small GW, Agdeppa ED, Kepe V, Satyamurthy N, Huang SC, Barrio JR. In vivo brain imaging of tangle burden in humans. J Mol Neurosci 2002;19:323-7.

4. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Int J Alzheimers Dis 2006;9:293-348.

5. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev 2002;54:285-322.

6. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993;73:229-308.

7. Johnson MB, Young AD, Marriott I. The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders. Front Cell Neurosci 2016;10:296.

8. Liu L, Markus I, Saghire HE, Perera DS, King DW, Burcher E. Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: a role for hemokinin-1? Neurogastroenterol Motil. 2011;23:475-83.

9. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martin JD, et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004;11:2045-81.

10. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 2014;94:265-301.

11. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63.

12. Martinez AN, Philipp MT. Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System. J Neurol neumed 2016;1:29-36.

13. Suvas S. Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis. J immunol 2017;199:1543-52.

14. Van Loy T, Vandersmissen HP, Poels J, Van Hiel MB, Verlinden H, Vanden Broeck J. Tachykinin-related peptides and their receptors in invertebrates: a current view. Peptides 2010;31:520-4.

15. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63.

16. Satake H, Aoyama M, Sekiguchi T, Kawada T. Insight into molecular and functional diversity of tachykinins and their receptors. Protein Pept Lett 2013;20:615-27.

17. Guard S, Watson SP. Tachykinin receptor types: classification and membrane signalling mechanisms. Neurochem Int 1991;18:149-65.

18. Page NM. New challenges in the study of the mammalian tachykinins. Peptides 2005;26:1356-68.

19. Barker R. Substance P and neurodegenerative disorders. A speculative review. Neuropeptides 1991;20:73-8.

20. Davoodian M, Boroumand N, Mehrabi Bahar M, Jafari AH, Asadi M, Hashemy SI. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer. Mol Biol Rep 2019;46:1285-93.

21. Gharaee N, Pourali R, Jafari AH, Hashemy SI. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer. Mol Biol Rep 2018;45:2257-62.

22. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999;340:1970-80.

23. Constantinidis J, Bouras C, Richard J. Putative peptide neurotransmitters in human neuropathology: a review of topography and clinical implications. Clin Neuropathol 1983;2:47-54.

24. Beal MF, Martin JB. Neuropeptides in neurological disease. Ann Neurol 1986;20:547-65.

25. Leake A, Ferrier IN. Alterations in neuropeptides in aging and disease. Drugs Aging 1993;3:408-27.

26. Rosser M, Emson P. Neuropeptides in degenerative disease of the central nervous system. Trends Neurosci 1982;5:399-401.

27. US VE, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931;72:74-87.

28. Mussap CI, Geraghty DP, Burcher E. Tachykinin receptors: a radioligand binding perspective. J Neurochem 1993;60:1987-2009.

29. Chen XY, Du YF, Chen L. Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease. Front Mol Neurosci 2018;11:493.

30. Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int 2008;53:103-11.

31. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J Mol Biol 1991;218:149-63.

32. Kirschner DA, Inouye H, Duffy LF, Sinclair A, Lind M, Selkoe DJ. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro.
33. Severini C, Petrella C, Calissano P. Substance P and Alzheimer&pos;s Disease: Emerging Novel Roles. Curr Alzheimer Res 2016;13:964-72.
34. El-Agnaf OM, Irvine GB, Fitzpatrick G, Glass WK, Guthrie DJ. Comparative studies on peptides representing the so-called tachykinin-like region of the Alzheimer Abeta peptide [Abeta(25-35)]. Biochem J 1998;336:419-27.
35. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science (New York, NY). 1990;250:279-82.
36. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci 1991;88:7247-51.
37. Mitsuhashi M, Akitaya T, Turk CW, Payan DG. Amyloid beta protein substituent peptides do not interact with the substance P receptor expressed in cultured cells. Mol Brain Res 1991;11:177-80.
38. Di Stefano M, Allepo G, Casabona G, Genazzani A, Scapagnini U, Nicotelli F. Amyloid beta protein does not interact with tachykinin receptors coupled to inositol phospholipid hydrolysis in human astrocytoma cells. Brain res 1993;600:166-8.
39. Kimura H, Schubert D. Amyloid beta-protein activates tachykinin receptors and inositol trisphosphate accumulation by synergy with glutamate. Proc Natl Acad Sci 1993;90:7508-12.
40. Koh JY, Yang LL, Cotman CW. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990;533:315-20.
41. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-89.
42. Lenard L, Laszlo K, Kertes E, Ollmann T, Peczely L, Kovacs A, et al. Substance P and neurotensin in the limbic system: Their roles in reinforcement and memory consolidation. Neurosci Biobehav Rev 2018;85:1-20.
43. Quigley Jr B, Kowall N. Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience 1991;41:41-60.
44. Beal MF, Mazurek MF. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology 1987;37:1205-9.
45. Martinez M, Frank A, Hernanz A. Relationship of interleukin-1β and β2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neuroimmunol 1993;48:235-40.
46. Johansson P, Almqvist EG, Wallin A, Johansson JO, Andreasson U, Blennow K, et al. Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. Neurosci Lett 2015;609:58-62.
47. Cramer H, Schaudt D, Riessler K, Strubel D, Warter J-M, Kuntzmann F. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. J Neurology 1985;232:346-51.
48. Rosler N, Wichart I, Jellinger KA. Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients. Neurosci Lett 2001;299:117-20.
49. Crystal HA, Davies P. Cortical Substance P-Like Immunoreactivity in Cases of Alzheimer's Disease and Senile Dementia of the Alzheimer Type. J neurochem 1982;38:1781-4.
50. Davies P, Maloney A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;308:1403.
51. Bellemère G, Morain P, Vaudry H, Jégou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and α-melanocyte-stimulating hormone breakdown in the rat brain. J neurochem 2003;84:919-29.
52. Ishiura S, Tsukahara T, Tabira T, Shimizu T, Arahata K, Sugita H. Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase. FEBS lett 1990;260:131-4.
53. Yoshida K, NakAajima S, Ootani T, Saito A, Amano N, Takano K, et al. Serum prolyl endopeptidase activities of patients with senile dementia of the Alzheimer type and of those with vascular dementia. J Clin Biochem Nutr 1996;21:227-35.
54. Ferrier I, Cross A, Johnson J, Roberts G, Crow T, Corsellis J, et al. Neuropeptides in Alzheimer type dementia. J Neurol Sci 1983;62:159-70.
55. Yates C, Harmar A, Rosie R, Sheward J, De Levy GS, Simpson J, et al. Thrytropin-releasing hormone, luteinizing hormone-releaseing hormone and substance P immuno-reactivity in postmortem brain from cases of Alzheimer-type dementia and Down's syndrome. Brain res 1983;258:45-52.
56. Barker R, Larner A. Substance P and multiple sclerosis. Med Hypotheses 1992;37:40-3.
57. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain pathology 2007;17:210-8.
58. Podda G, Nyirenda M, Crooks J, Gran B. Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis. J Neuroimmune Pharmacol 2013;8:791-806.
The role of substance P

59. Constantinescu C, Gran B. The essential role of T cells in multiple sclerosis: a reappraisal. Biomed J 2014;37:34-40.
60. Weinstock JV. Substance P and the regulation of inflammation in infections and inflammatory bowel disease. Acta Physiol (Oxf) 2015;213:453-61.
61. Goode T, O’Connell J, Anton P, Wong H, Reeve J, O’Sullivan GC, et al. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 2000;47:387-96.
62. O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004;201:167-80.
63. Vilisaar J, Kawabe K, Braitech M, Aram J, Furtun Y, Fahey AJ, et al. Reciprocal regulation of substance P and IL-12/IL-23 and the associated cytokines, IFNγ/IL-17: A perspective on the relevance of this interaction to multiple sclerosis. J Neuroimmun Pharmaco 2015;10:457-67.
64. Hertz L, McFarlin DE, Waksman BH. Astrocytes: auxiliary cells for immune responses in the central nervous system? Immunol Today 1990;11:265-8.
65. Compton A, Scolding N, Wren D, Noble M. The pathogenesis of demyelinating disease: insights from cell biology. Trends Neurosci 1991;14:175-82.
66. Reineke EK, Johnson MJ, Ling C, Karman J, Lee J, Weinstock JV, et al. Substance P receptor mediated maintenance of chronic inflammation in EAE. J Neuroimmunoph 2006;180:117-25.
67. Kostyk S, Kowell N, Hauser S. Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain res 1989;504:284-8.
68. Rössler N, Reuner C, Geiger J, Rissler K, Cramer H. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease. Peptides 1990;11:181-3.
69. Thornton E, Vink R. Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease. Neural Regen Res 2015;10:1403-5.
70. Raffa RB. Possible role(s) of neurokins in CNS development and neurodegenerative or other disorders. Neurosci Biobehav Rev 1998;22:789-813.
71. Thornton E, Hassall MM, Corrigan F, Vink R. The NK1 receptor antagonist N-acetyl-1-trypophan reduces dyskinesia in a hemi-parkinsonian rodent model. Parkinsonism Relat Disord 2014;20:508-13.
72. Cenci MA, Lindgren HS. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 2007;17:665-71.
73. Thornton E, Vink R. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 2012;7:e34138.
74. Nutt DG, Mroz EA, Leeman SE, Williams AC, Engel WK, Chase TN. Substance P in human cerebrospinal fluid Reductions in peripheral neuropathy and autonomic dysfunction. Neurology 1980;30:1280-5.
75. Pezzoli G, Panerai A, Di Giulio A, Longo A, Passerini D, Carenzi A. Methionine enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. Neurology 1984;34:516-9.
76. Cramer H, Jost S, Reuner C, Milios E, Geiger J, Mundinger F. Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivity. Neuropeptides 1991;18:69-73.
77. Cramer H, Rissler K, Rössler N, Strubel D, Schaudt D, Kuntzmann F. Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. European neurology. 1989;29:1-5.
78. Chiba Y, Kawai K, Okuda Y, Munekata E, Yamashita K. Effects of Substance P and Substance P-(6-11) on Hormone Release from Isolated Perfused Pancreas: Their Opposite Actions on Rat and Canine Islets. Endocrinology 1985;117:1996-2000.
79. Mauborgne A, Javy-Agid F, Legrand J, Agid Y, Cesselin F. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain res 1983;268:167-70.
80. Tenovuo O, Rinne U, Viljanen M. Substance P immunoreactivity in the postmortem parkinsonian brain. Brain res 1984;303:113-6.
81. Barker R. Substance P and Parkinson's disease: a causal relationship? J Theor Biol 1986;120:353-62.
82. Thornton E, Tran TT, Vink R. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neuroscience lett 2010;481:64-7.
83. Emson P, Arregui A, Clement-Jones V, Sandberg B, Rossor M. Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain res 1980;199:147-60.
84. Bird ED. Chemical pathology of Huntington's disease. Annu Rev Pharmacol Toxicol 1980;20:533-51.
85. Davies J, Dray A. Substance P in the substantia nigra. Brain Res 1976;107:623-7.
86. Kubota Y, Inagaki S, Kito S. Innervation of substance P neurons by catecholaminergic terminals in the neostriatum. Brain Res 1986;375:163-7.
87. Beal MF, Ellison DW, Mazurek MF, Swartz KJ, Malloy JR, Bird ED, et al. A detailed examination of substance P in pathologically graded cases of Huntington's disease. J Neurol Sci 1988;84:51-61.
88. Kanazawa I, Bird E, O'Connell R, Powell D. Evidence for a decrease in substance P content of substantia nigra in...
Huntington’s chorea. Brain Res 1977;120:387-92.

89. Buck SH, Burks TF, Brown MR, Yamamura HI. Reduction in basal ganglia and substantia nigra substance P levels in Huntington’s disease. Brain res 1981;209:464-9.

90. Gale J, Bird E, Spokes E, Iversen L, Jessell T. Human brain substance P: distribution in controls and Huntington’s chorea. J Neurochem 1978;30:633-4.

91. Leigh PN, Ray-Chaudhuri K. Motor neuron disease. Neurol Neurosurg Psychiatry 1994;57:886-96.

92. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006;7:710-23.

93. Gruzman A, Wood WL, Alpert E, Prasad MD, Miller RG, Rothstein JD, et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2007;104:12524-9.

94. Matsuishi T, Nagamitsu S, Shoji H, Itoh M, Takashima S, Iwaki T, et al. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. J Neural Transm 1999;106:943-8.

95. Dietl M, Sanchez M, Probst A, Palacios J. Substance P receptors in the human spinal cord: decrease in amyotrophic lateral sclerosis. Brain res 1989;483:39-49.

96. Gillberg PG, Aquilonius SM, Eckernas SA, Lundqvist G, Winblad B. Choline acetyltransferase and substance P-like immuno-reactivity in the human spinal cord: changes in amyotrophic lateral sclerosis. Brain Res 1982;250:394-7.